Steatotic Liver Disease Clinical Trials

57 recruitingLast updated: May 13, 2026

There are 57 actively recruiting steatotic liver disease clinical trials across 47 countries. Studies span Not Applicable, Phase 2, Phase 1, Early Phase 1, Phase 3, Phase 4. Top locations include Barcelona, Spain, La Jolla, California, United States, San Francisco, California, United States. Updated daily from ClinicalTrials.gov.


Steatotic Liver Disease Trials at a Glance

57 actively recruiting trials for steatotic liver disease are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Not Applicable with 20 trials, with the heaviest enrollment activity in Barcelona, La Jolla, and San Francisco. Lead sponsors running steatotic liver disease studies include Regeneron Pharmaceuticals, University of California, San Diego, and University of California, San Francisco.

Browse steatotic liver disease trials by phase

Treatments under study

About Steatotic Liver Disease Clinical Trials

Looking for clinical trials for Steatotic Liver Disease? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Steatotic Liver Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Steatotic Liver Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 57 trials

Recruiting
Not Applicable

EVOO and Metabolic Liver Health in MASLD

OverweightMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis60 enrolled1 locationNCT07412444
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled342 locationsNCT06318169
Recruiting
Phase 2

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

HIV (Human Immunodeficiency Virus)MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Naga P. Chalasani120 enrolled10 locationsNCT07143968
Recruiting
Phase 2

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseFatty Liver Disease, NonalcoholicOverweight (BMI > 25)
AB Biotics, SA60 enrolled1 locationNCT07193927
Recruiting
Not Applicable

Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis

Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)Metabolic Adaptation to High-Intensity Interval Training
Universidad San Sebastián30 enrolled1 locationNCT07552727
Recruiting
Not Applicable

Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseNormobaric Hypoxia
University of Trieste20 enrolled1 locationNCT07073326
Recruiting
Phase 1Phase 2

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals132 enrolled3 locationsNCT06836609
Recruiting
Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 1Phase 2

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Healthy VolunteersMetabolic dysfunction–associated steatotic liver disease (MASLD)
Regeneron Pharmaceuticals172 enrolled6 locationsNCT05648214
Recruiting
Not Applicable

Time-restricted Feeding in MASLD

Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Universität des Saarlandes120 enrolled1 locationNCT07530809
Recruiting

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

MASLDNAFLD (Nonalcoholic Fatty Liver Disease)NAFLD+1 more
University of California, San Diego26 enrolled1 locationNCT07518784
Recruiting
Not Applicable

Advanced Fibrosis Detection for MASLD in Primary Care

Metabolic Dysfunction-Associated Steatotic Liver Disease
Medical University of South Carolina225 enrolled1 locationNCT07159386
Recruiting
Not Applicable

A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Alcohol-Related Liver Disease
The University of Hong Kong50 enrolled1 locationNCT07450144
Recruiting
Phase 1

Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation

Metabolic Dysfunction-Associated Steatotic Liver Disease
Leeuwenhoek Laboratories Co. Ltd.40 enrolled1 locationNCT07488975
Recruiting
Phase 2

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

Hepatic SteatosisNonalcoholic SteatohepatitisMetabolic-Associated Steatotic Liver Disease
Hudson Biotech120 enrolled1 locationNCT07481734
Recruiting

Expanded Studies on the SCAPIS Stockholm Reexamination Cohort

Heart FailureCoronary Artery DiseaseOral Microbiota+9 more
Danderyd Hospital1,400 enrolled1 locationNCT07476703
Recruiting

The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register

Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 Diabetes (T2DM)
Chinese University of Hong Kong1,000 enrolled1 locationNCT07437157
Recruiting

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Fondazione Policlinico Universitario Agostino Gemelli IRCCS500 enrolled1 locationNCT07440511
Recruiting
Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Not Applicable

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Non alcoholic steato hepatitis (NASH)Liver Fibrosis/NASHMetabolic dysfunction–associated steatotic liver disease (MASLD)
Université de Sherbrooke36 enrolled1 locationNCT06843148